The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer's Disease and Other Neurodegenerative Disorders
Overview
Affiliations
Peroxisome proliferator activated receptor alpha (PPAR-α) belongs to the family of ligand-regulated nuclear receptors (PPARs). These receptors after heterodimerization with retinoid X receptor (RXR) bind in promotor of target genes to PPAR response elements (PPREs) and act as a potent transcription factors. PPAR-α and other receptors from this family, such as PPAR-β/δ and PPAR-γ are expressed in the brain and other organs and play a significant role in oxidative stress, energy homeostasis, mitochondrial fatty acids metabolism and inflammation. PPAR-α takes part in regulation of genes coding proteins that are involved in glutamate homeostasis and cholinergic/dopaminergic signaling in the brain. Moreover, PPAR-α regulates expression of genes coding enzymes engaged in amyloid precursor protein (APP) metabolism. It activates gene coding of α secretase, which is responsible for non-amyloidogenic pathway of APP degradation. It also down regulates β secretase (BACE-1), the main enzyme responsible for amyloid beta (Aβ) peptide release in Alzheimer Diseases (AD). In AD brain expression of genes of PPAR-α and PPAR-γ coactivator-1 alpha (PGC-1α) is significantly decreased. PPARs are altered not only in AD but in other neurodegenerative/neurodevelopmental and psychiatric disorder. PPAR-α downregulation may decrease anti-oxidative and anti-inflammatory processes and could be responsible for the alteration of fatty acid transport, lipid metabolism and disturbances of mitochondria function in the brain of AD patients. Specific activators of PPAR-α may be important for improvement of brain cells metabolism and cognitive function in neurodegenerative and neurodevelopmental disorders.
Feng Y, Cao S, Shi Y, Sun A, Flanagan M, Leverenz J Alzheimers Dement. 2025; 21(2):e14595.
PMID: 39985481 PMC: 11846481. DOI: 10.1002/alz.14595.
Metabolic reprogramming in the spinal cord drives the transition to pain chronicity.
Mabou Tagne A, Fotio Y, Lee H, Jung K, Katz J, Ahmed F bioRxiv. 2025; .
PMID: 39975205 PMC: 11838349. DOI: 10.1101/2025.01.30.635746.
Singh S, Singh R Mol Biol Rep. 2025; 52(1):173.
PMID: 39880979 DOI: 10.1007/s11033-025-10297-6.
Alfei S, Zuccari G Int J Mol Sci. 2025; 26(2).
PMID: 39859559 PMC: 11766176. DOI: 10.3390/ijms26020844.
The Mitochondrial Blueprint: Unlocking Secondary Metabolite Production.
Li Y, Zhang Y, He X, Guo Z, Yang N, Bai G Metabolites. 2024; 14(12).
PMID: 39728492 PMC: 11677534. DOI: 10.3390/metabo14120711.